Paul Magrez

Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium.

BARC NV provides central laboratory services. It specializes in testing wide range of fields including virology, microbiology, clinical pathology, and genetics. The firm offers biobanking, cerba specimen, custom test development, data management, investigator support, project management, and logistics. The company is headquartered in Ghent, Belgium.

Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France.

Laboratoire Cerba SA provides medical research services. It conducts tests in the fields of virology, autoimmune disease, allergy, endocrinology, oncology, toxicology and molecular genomics. The company was founded in 1967 and is headquartered in Saint-Ouen-l'Aumône, France.

UCB Pharma SA discovers and develops biopharmaceutical products. It is a biopharmaceutical company focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is headquartered in Brussels, Belgium.

Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.